EUCTR2009-015811-42-PT进行中（未招募）1 期
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638 - EDGE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria in order to
- •participate in this study:
- •1.The patient is willing and able to provide signed informed consent
- •prior to any study-related procedures.
- •2.The patient is =18 years of age.
- •3.The patient has a diagnosis of Gaucher disease type 1 confirmed by a documented deficiency of acid ß glucosidase activity by enzyme assay.
- •The patient may be previously untreated, off prior treatment, or
- •receiving enzyme replacement therapy for Gaucher disease.
- •4.The patient meets all of the following criteria at the time of Screening:
- •Hemoglobin level =9 g/dL (mean of 2 measurements);
- •Platelet count =70,000/mm3 (mean of 2 measurements);
- •Spleen volume =25 multiples of normal (MN);
- •Liver volume =2.0 MN.
- •5.The patient consents to provide a blood sample for genotyping for Gaucher disease and for cytochrome P450 2D6 (CYP2D6) to categorize the patient's predicted rate of metabolism, if these genotyping results are not already available for the patient.
- •6.Female patients of childbearing potential must have a documented
- •negative pregnancy test prior to administration of the first dose of Genz-112638 in this study. In addition, all female patients of childbearing potential must use a medically accepted form of contraception throughout the study, i.e., either a barrier method or hormonal contraceptive with norethindrone and ethinyl estradiol or similar active components.
- •7.The patient is willing to abstain from consumption of grapefruit,
- •grapefruit juice, or grapefruit products for 72 hours prior to
- •administration of the first dose of Genz 112638 and throughout the
- •duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Patients will be excluded from participation in this study if they meet
- •any of the following exclusion criteria:
- •1.The patient is participating in GZGD02607 study, A Phase 3,
- •Randomized, Multi-Center, Multi-National, Open-Label, Active
- •Comparator Study to Evaluate the Efficacy and Safety of Genz 112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme, or is eligible for inclusion in GZGD02607 (while enrollment is ongoing) and has access to a physician participating in GZGD02607.
- •The patient is participating in GZGD02507 study, A Phase 3,
- •Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
- •Confirming the Efficacy and Safety of Genz 112638 in Patients with
- •Gaucher Disease Type 1, or is eligible for inclusion in GZGD02507 (while enrollment is ongoing) and has access to a physician participating in GZGD02507.
- •2.The patient received miglustat within 6 months prior to administration of the first dose of Genz 112638 in this study.
- •3.The patient has had a partial or total splenectomy within 3 years prior to administration of the first dose of Genz 112638 in this study.
- •4.The patient has any evidence of neurologic disorder (e.g., peripheral neuropathy, tremor, seizures, Parkinsonism or cognitive impairment) or pulmonary involvement (e.g., pulmonary hypertension) as related to Gaucher disease.
- •5.The patient is transfusion-dependent.
- •6.The patient has a documented deficiency of iron, vitamin B-12, or
- •folate that requires treatment not yet initiated or, if initiated, the patient has not been stable under treatment for at least 3 months prior to administration of the first dose of Genz 112638 in this study.
- •7.The patient has documented prior esophageal varices or clinically
- •significant liver infarction or current liver enzymes (alanine
- •transaminase [ALT]/aspartate aminotransferase [AST]) or Total
- •Bilirubin > 2 times the upper limit of normal (ULN), unless the patient has a diagnosis of Gilbert Syndrome.
- •8.The patient has any clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (including hypokalaemia or hypomagnesemia), or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation in the study.
- •9.The patient is known to have any of the following: Clinically significant coronary artery disease including history of myocardial infarction [MI] or ongoing signs or symptoms consistent with cardiac ischemia or heart failure; or clinically significant arrhythmias or conduction defect such as 2nd or 3rd degree atrioventricular (AV) block, complete bundle branch block, prolonged QTc interval, or sustained ventricular tachycardia (VT).
- •10.The patient is known to have tested positive for the human
- •immunodeficiency virus (HIV) antibody, Hepatitis C antibody, or
- •Hepatitis B surface antigen.
- •11.The patient has received an investigational product (other than Genz-112638) within 30 days prior to administration of the first dose of Genz-112638 in this study.
- •12.The patient is scheduled for in-patient hospitalization, including
- •elective surgery, during the study.
- •13.The patient has a history of cancer, with the exception of basal cell carcinoma, within 5 years prior to administration of the first dose of Genz 112638 in this study.
- •14.The patient is pregnant or lactating.
- •15.The patient has received any medication that may caus
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638 - EDGEGaucher Disease Type IMedDRA version: 12.1Level: PTClassification code 10018048Term: Gaucher's diseaseEUCTR2009-015811-42-GRGenzyme Europe B.V.234
进行中（未招募）
不适用
A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic goals with Enzyme Replacement Therapy - ENCOREGaucher Disease type IMedDRA version: 9.1Level: PTClassification code 10018048Term: Gaucher's diseaseEUCTR2008-005223-28-CZGenzyme Europe B.V.186
进行中（未招募）
1 期
A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have Reached Therapeutic Goals with Enzyme Replacement Therapy - ENCOREGaucher Disease type IMedDRA version: 9.1Level: PTClassification code 10018048Term: Gaucher's diseaseEUCTR2008-005223-28-NLGenzyme Europe B.V.159
进行中（未招募）
不适用
A Study of Eliglustat Tartrate (Genz-112638) in Patients with Gaucher Disease Who Have Reached Thereapeutic Goals with Enzyme Replacement TherapyGaucher Disease type IMedDRA version: 18.0Level: PTClassification code 10018048Term: Gaucher's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-005223-28-DEGenzyme Europe B.V.150
进行中（未招募）
1 期
A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme - ENCOREGaucher Disease type IMedDRA version: 9.1Level: PTClassification code 10018048Term: Gaucher's diseaseEUCTR2008-005223-28-FRGenzyme Europe B.V.159